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ABSTRACT 
An active surveillance system of invasive pneumococcal disease (IPD) started on September 2008 in Lombardy, Italy, 
among children aged less than 60 months and admitted for suspicion of IPD at emergency room of ten hospitals. This 
study examined the clinical characteristics of children enrolled up to December 2010, that is just before the introduction 
in this region of voluntary mass vaccination, free of charge, based on the 13-valent pneumococcal conjugate vaccine 
(PCV13). Two hundred fifty one children were suspected and 20 were confirmed as having IPD, based on isolation of 
Streptococcus pneumoniae from blood. Thirty-nine percent of children had received pneumococcal vaccination pre- 
viously, and full vaccination with three doses of hepta-valent vaccine (PCV7) had been administered in 21.4%. Co-mor- 
bidity conditions were more frequent in children with confirmed than non-confirmed IPD (10.0% vs. 0.9%). The annual 
incidence rate of confirmed IPD was 28.6/100,000 (binomial 95% confidence interval, 18.6 to 44.1/100,000). Among 
confirmed IPD children, 11 exhibited pneumonia with bacteremia, 6 bacteremia without focus, 2 septicemia, 1 meningi-
tis. Seventeen (85%) isolates were identified, and nine serotypes. The overall serotype coverage was 29.4% for PCV7 
and 82.3% for PCV13. In non-vaccinated children, the coverage of PCV7 and PCV13 was 41.7% and 75.0%, respect- 
tively. Non-vaccine serotypes 12B, 15C, and 23B were identified. Antibiotic resistance was found in seven children, 
that is against penicillin (serotype 15C), erythromycin (14, 19A, 19F), tetracycline (15C, 19F), chloramphenicol (23F), 
and trimethoprim-sulfamethoxazole (23F). Two of these children had received antibiotic therapy (penicillin or azithro-
mycin) during the week before hospital admission. The coverage vaccination rate in Lombardy was relatively low dur-
ing the surveillance period and serotype distribution widespread. The introduction of PCV13 and a mass vaccination 
program in young children might impact positively on invasive pneumococcal disease in this surveilled population. Ac- 
tive long-term surveillance of non-vaccine serotypes is required wordwide. 
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1. Introduction 
Streptococcus pneumoniae (S. pneumoniae) is a lead- 
ing cause of invasive infection and vaccine-preventable 
deaths among young children [1-4]. Decline in invasive 
pneumococcal disease (IPD) has been observed in coun-
tries which introduced the heptavalent pneumococcal 
conjugate vaccine (PCV7) in their immunization pro-
grams [5-6], with higher reduction in the US, where also 
decline in IPD mortality occurred [7]. While pneumo-
coccal serotypes may vary across geographical locations, 
also resulting in different vaccine coverage [2,8], non- 
vaccine serotype replacement may emerge worldwide 
[9,10]. The World Health Organization recommends to 
monitor actively the effect of pneumococcal vaccination 
[1]. 
In Italy, few local studies have been conducted in the 
past in children aged less than 60 months [11-15]. Re-
cently Azzari et al. [16] reported merged national data on 
Italian children aged 0 - 16 years, which however fo-
cused on serotype coverage only. The heptavalent pneu-
mococcal conjugate vaccine PCV7 was licensed in Italy 
in 2001 and progressively introduced since 2003, rec-
ommended firstly in at-risk children aged less than 5 
years and then planned on different regional vaccination 
strategies. This setting has contributed to make broad 
difference in the vaccination coverage across geographi-
*The Invasive Pneumococcal Disease Lombardy Study Group (see Ap-
pendix A). 
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cal areas. In Lombardy, PCV7 was initially offered to 
at-risk children free of charge, otherwise available at the  
private market on voluntary demand with co-payment of 
about USD65 per dose up to December 2009. Based on 
the current national plan for vaccinations [17] and re-
gional directives, the pneumococcal conjugate vaccine 
PCV13 is now offered in Lombardy on voluntary de-
mand and free of charge, and vaccination has been 
scheduled in infants to be administered at three single 
doses at 3, 5 - 6, and 11 - 12 months of age [17]. 
Indeed, while Lombardy is a crucial region with around 
10,000,000 resident people in 2011, the characteristics of 
IPD in young children, including the pneumococcal se-
rotype distribution, have been never actively investi- 
gated. 
The main objective of this study was to describe the 
clinical characteristics of the invasive pneumococcal 
disease in young children residing in the North-West 
Lombardy, Italy, and to determine the serotype distribu-
tion of S. pneumoniae occurring just before the introduc-
tion of the PCV13, that was licensed in Italy for com-
mercialization on April 30, 2010. 
These data would provide general epidemiological in-
formation useful to better examine the traits of invasive 
pneumococcal disease in young children, and further to 
help the Health Authorities and industry for hopefully 
improving immunization strategies. 
2. Methods 
2.1. Setting 
This study is a part of an active surveillance of IPD in 
young children that started on September 01, 2008, in 
North-West Lombardy, Italy, also including the munici-
pality of Milan. Cases of suspected IPD were collected 
from ten hospitals homogeneously located in the area 
delimited by four Reference Local Health Authorities 
districts. This study analyzed children enrolled up to De-
cember 31, 2010, that is before of the introduction of a 
new regular vaccination strategy and implementation of 
the PCV13 in Lombardy. The scrutinized area comprised 
at the beginning of the surveillance around 3,500,000 
people, including 130,000 children aged less than 60 
months, of whom 30,000 (12,000 aged less than 24 
months) referenced to the participant hospitals. 
2.2. Subjects 
Children admitted at emergency room of the hospitals 
were assessed for eligibility. Inclusion criteria were: age 
at admission 28 days - 59 months; being residing in the 
monitored area; suspicion of IPD, that is any S. pneumo-
niae clinical syndrome; negative urinalysis for urinary 
tract infections based on fast urine test; C-reactive pro- 
tein > 15 mg/L. The additional inclusion criterion and/or 
body (rectal) temperature ≥ 38˚C was considered in chil- 
dren aged ≤ 36 months, as it may be per se suggestive of 
IPD within this range of age [18]. The exclusion criterion 
was refusal of parents or the legal guardian to give writ-
ten consent. Urinalysis was performed by Aution sticks- 
10EA (ARKRAY Europe, B.V., Amstelveen, The Neth-
erlands). C-reactive protein was measured by direct im-
munoturbidimetry (Tina-Quant, Roche Diagnostics, 
Hoffmann-La Roche Ltd, Basel, Switzerland). 
2.3. Ethics 
The study was carried out in accordance with the Decla-
ration of Helsinki and Good Clinical Practice guidelines. 
The ethics committee of each hospital approved the study 
protocol. Written informed consent was obtained from 
the parents or legal guardian after the study had been 
fully explained. 
2.4. Case Definition 
A case of confirmed IPD was defined in accordance with 
the Centers for Disease Control and Prevention (Atlanta, 
GA, USA) [19, 20]. Definition of specific IPD syndrome 
was in accordance with the International Classification of 
Diseases-9 [21]. 
2.5. Identification of Isolates 
Blood samples were taken in children within 24 h of re-
cruitment. Cerebrospinal fluid samples were additionally 
taken in children with clinical syndrome of sepsis and/or 
meningitis for confirmation. S. pneumoniae isolates were 
identified by standardized laboratory procedures. Fresh 
cultures of isolates on blood agar plates and in Amies 
medium swab were sent to the central reference labora-
tory (Milan, Italy) for analysis and stored on beads at 
–70˚C. Isolates were then confirmed for S. pneumoniae 
by testing for alpha haemolysis on blood agar, optochin 
susceptibility and bile solubility. 
2.6. Serotyping and Antimicrobial Susceptibility 
Serotyping was based on Omni serum (Statens Serum 
Institut, Copenhagen, Denmark) that includes antibodies 
to all recognized S. pneumoniae serotypes. A suspension 
of the test organism was prepared in saline solution 0.9% 
from well isolated colonies grown on sheep blood agar 
plates for 18 to 24 h in 5% CO2 at 35˚C. One drop of this 
suspension was mixed with 1 drop of antiserum and 1 
drop of methylene blue and, after incubation at room 
temperature for 10 min, examined at 1000× magnifica-
tion. Visible evidence of capsular swelling with Omni 
serum, i.e., a positive Quellung reaction, was considered  
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positive, and followed by type specific antisera. Antimi- 
crobial susceptibility against penicillin G, ceftriaxone, 
erythromycin, tetracycline, trimethoprim-sulfamethoxa- 
zole, chloramphenicol, levofloxacin, linezolid and van-
comycin was performed by the E test method (AB Bio-
disk, Solana, Sweden) on Mueller-Hinton agar supple-
mented with 5% defibrinated sheep blood (bioMérieux 
Italia Spa, Bagno a Ripoli, Italy). The minimal inhibitory 
concentration was defined in accordance with the Clini-
cal and Laboratory Standards Institute breakpoints [22]. S. 
pneumoniae ATCC 49619 was used as control strain [22].  
2.7. Statistical Analysis 
Comparison between independent groups was performed 
by the Chi-square or Fisher’s exact test or Mann-Whit-
ney U test, as appropriate. Significance was posed at P < 
0.05 (two-tails). The statistical analyses were done using 
the SPSS software, version 17.0 for Windows (SPSS Inc., 
Chicago, IL). 
3. Results 
Two hundred fifty one children (140 boys, 111 girls; mean 
age [SD] 27.5 [16.8] months) were recruited. Blood test-
ing data were available in 236 cases, and 20 (13 boys, 7 
girls) were confirmed as having IPD. All of them were hos- 
pitalized. No fatality outcome occurred during hospitali-
zation. The pooled annual incidence rate of confirmed IPD 
was 28.6/100,000 (binomial 95% confidence interval, 18.6 
to 44.1/100,000), that is 30.0/100,000 (16.0 to 46.9/100,000) 
in infants and 26.2/100,000 (14.8 to 48.9/100,000) in chil- 
dren aged 2 - 4 years. 
Table 1 reports the baseline characteristics of children 
by IPD status. The rate of co-morbidity conditions was 
higher in children with confirmed than non-confirmed 
(suspected) IPD. No child was human immunodeficiency 
virus positive. 
 
Table 1. Baseline characteristics of the examined children, by IPD status. 
IPD 
Characteristic All recruited (n = 251)
Non-confirmed (n = 216) Confirmed (n = 20) 
P-value† 
Age (y)     
<2 119 (47.4) 104 (48.1) 9 (45.0) 0.787 
2 - 4 142 (52.6) 112 (51.9) 11 (55.0)  
Gender (male) 140 (55.8) 116 (53.7) 13 (65.0) 0.332 
Race (white)†† 204 (81.3) 176 (81.5) 18 (90.0) 0.541 
Having been breastfed (yes) 198 (78.9) 175 (81.0) 15 (75.0) 0.555 
Siblings (yes) 125 (49.8) 110 (50.9) 8 (40.0) 0.350 
Having a parent smoking (yes) 76 (23.0) 70 (32.2) 5 (25.0) 0.620 
Attending a community (yes) 106 (42.4) 90 (41.9) 12 (60.0) 0.117 
Congenital disease 11 (4.4) 10 (4.6) 1 (5.0) 1.00 
Co-morbidity conditions††† (yes) 4 (1.6) 2 (0.9) 2 (10.0) 0.037* 
Having received pneumococcal vaccine before (yes) 98 (39.0) 86 (39.8) 6 (30.0) 0.389 
Type (conjugate/polysaccharide) 87/11 76/10 5/1 0.545 
Doses (n)††††     
1 25 (25.5) 24 (27.9) 1 (16.7)  
2 48 (49.0) 43 (50.0) 2 (33.3) 0.242 
3 21 (21.4) 15 (17.4) 3 (50.0)  
4 4 (4.1) 4 (4.7) 0 (0.0)  
Median (range) age at the first dose of vaccine (mo)†††† 5.5 (2 - 40) 5.0 (2 - 36) 4.5 (3 - 40) 0.540 
Having received antibiotic therapy during the week 
before recruitment (yes) 86 (34.3) 79 (36.6) 2 (10.0) 0.015
* 
Data are number of children (percentage within group) of children, except age at the first vaccination. †Significance of comparison between IPD groups. 
(Chi-square test, exact Fisher’s test or Mann-Whitney U test). *Statistically significant. ††Non-white races include: Afro/Afro-American (n = 24), Asian (n = 7), 
other or mixed-race (n = 16). †††Immunodeficiency (n = 1), sickle cell anemia (n = 2), cardiovascular disease and/or chronic liver disease (n = 1). ††††In children 
who received pneumococcal vaccine. 
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Table 2 reports the clinical characteristics of children 
by IPD status. No significant difference occurred be-
tween children with confirmed or non-confirmed (sus-
pected) IPD, except for clinical syndrome (P < 0.0001). 
In the IPD group, thoracic radiography was negative in 6 
(30.0%) children, and revealed lobar or bronchial pneu-
monia in respectively 5 (25.0%) and 9 (45.0%) children; 
the distribution of clinical syndrome differed between 
infants and children aged 2 - 4 years (P = 016), that is: 
pneumonia 22.2% vs. 81.8%, bacteremia 44.4% vs. 
18.2%, septicemia 22.2% vs. 0%, meningitis 11.1% vs. 
0%. Blood leukocytes were higher in infants than chil-
dren aged 2 - 4 years (median [range] 27.7 [17.1 - 41.0] 
vs. 20.2 [2.1 - 26.4] × 109/L; P = 0.023). 
Table 3 shows the serotype distribution of IPD iso-
lates by vaccination status. The PCV13 serotypes 1, 7F, 
19A were the most frequently observed (52.9%) of iden-
tified serotypes. Five of them were found in children who 
had received respectively one (one case, age 55 months, 
serotype 1), two (one case, age 37 months, serotype 19A) 
or three (3 cases, age 24 months, serotype 1; age 27 
months, serotype 7F; age 15 months, serotype 19A) 
doses of PCV7. PCV7 serotypes 14, 19F, 23F were 
found in 5/14 (35.7%) of non-vaccinated children. Sero-
types 12B, 23B and 15C, not included in any pneumo-
coccal vaccine, were identified in non-vaccinated infants. 
Seven (41.1%) of typified isolates showed antibiotic re-
sistance. Resistance was found against: penicillin (one 
case; serotype 15C), erythromycin (5 cases; serotypes 14, 
19A, 19F [n = 2]; 23F), tetracycline (4 cases; serotypes 
15C, 19F [n = 2], 23F), chloramphenicol (one case; 23F), 
and trimethoprim-sulfamethoxazole (one case; serotype 
23F). Multiple resistance was found for serotypes 15C, 
19F, and 23F. Two of seven children who exhibited a 
serotype with any antibiotic resistance had received anti-
biotic therapy during the week before hospital admission, 
and were affected by pneumonia. One child (35 months) 
had received penicillin and showed serotype 19F resis-
tant to erythromycin and tetracycline. One child (41 
months) had received azithromycin and showed serotype 
23F resistant against erythromycin, chloramphenicol and 
trimethoprim-sulfamethoxazole. 
Serotypes 1, 7F, 14, 19F, 23F caused pneumonia, 19A, 
19F, 23B bacteremia without an obvious focus, 12B and 
23B septicemia, and serotype 15C caused meningitis. 
The overall expected serotype coverage rate, esti-
mated on typified IPD cases, was 29.4% for PCV7 and 
82.3% for PCV13. In non-vaccinated children, the cov-
erage of PCV7 and PCV13 was 41.7% and 75.0%, re-
spectively. 
 
Table 2. Clinical characteristics at hospital admission of children and syndrome, by IPD status. 
IPD 
Characteristic All recruited (n = 251) 
Non-confirmed (n = 216) Confirmed (n = 20) 
P-value† 
Body (rectal) temperature (˚C)     
Median (range) 38.9 (36.3 - 41.0) 38.5 (36.3 - 41.0) 39.0 (38.5 - 39.7) 0.438 
38˚C (yes) 212 (84.5) 182 (84.3) 18 (90.3) 0.747 
Blood leukocytes (× 109/L)     
Median (range) 19.1 (2.1 - 50.3) 19.1 (2.6 - 50.3) 21.0 (2.1 - 41.0) 0.165 
C-reactive protein (mg/L)     
Median (range) 90.2 (2.1 - 450.0) 91.1 (5.0 - 450.0) 140.9 (4.1 - 400.0) 0.146 
10 11 (4.4) 5 (2.3) 1 (0.5)  
11 - 40 59 (23.7) 51 (23.6) 3 (15.0)  
41 - 200 126 (50.6) 114 (52.8) 10 (50.0)  
>200 53 (21.3) 46 (21.3) 6 (30.0)  
Syndrome (ICD-9)    <0.0001 
Pneumonia 167 (67.1) 146 (67.6) 11 (55.0)  
Bacteremia 6 (2.4) 0 (0.0) 6 (30.0)  
Septicemia 4 (1.6) 2 (0.9) 2 (10.0)  
Meningitis 2 (0.8) 1 (0.5) 1 (5.0)  
Other 70 (28.1) 67 (31.0)   
Data are number of children (percentage within group) or median (range). Percentages may not sum to 100 because of rounding. †Significance of comparison 
between IPD groups (Chi-square test, exact Fisher’s test or Mann-Whitney U test). 
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Table 3. Serotype distribution of S. pneumoniae typified isolates in children with confirmed IPD by status of pneumococcal 
vaccination. 
 Having received pneumococcal vaccination before 
Serotype 
All confirmed IPD (n = 20) Yes (n = 6) No (n = 14) 
Included in PCV7/PCV13 5 [2, 3] (5)  5 [2, 3] (5) 
14 1 [1, 0] (1)  1 [1, 0] (1) 
19F 2 [0, 2] (2)  2 [0, 2] (2) 
23F 2 [1, 1] (2)  2 [1, 1] (2) 
Included in PCV13 9 [3, 6] (1) 5 [1, 4] 4 [2, 2] (1) 
1 2 [0, 2] 2 [0, 2]  
7F 4 [1, 3] 1 [0, 1] 3 [1, 2] 
19A 3 [2, 1] (1) 2 [1, 1] 1 [1, 0] 
Not included in any pneumococcal vaccine 3 [2, 1] (1)  3 [2, 1] (1) 
12B 1 [1, 0]  1 [1, 0] 
15C 1 [1, 0] (1)  1 [1, 0] (1) 
23B 1 [1, 0]  1 [1, 0] 
Not availablea 3 [1, 2] 1 [1, 0] 2 [0, 2] 
Data are number of cases. Number of children aged < 24 or 24 - 59 months within square brackets. Number of cases showing any antibiotic resistance within 
round brackets, when different from zero. aNot available = 2 non-viable cultures, 1 blood sample damaged. 
 
4. Discussion 
In the monitored area, before the introduction of PCV13, 
around 25% of confirmed IPD were caused by PCV7 
serotypes, a proportion that is comparable with recent 
data from some European countries (e.g. 17% in Portugal 
[23]) but is higher than in the US (around 2 - 3% [5,24]). 
As pointed out by Aguiar et al. [23], a major factor for 
the difference may be the different vaccination programs 
adopted across geographical locations. Indeed, in this 
study 39% of children with suspected IPD had received 
pneumococcal vaccination, and full vaccination with 
three doses of PCV7 was administered in 21.4% of chil-
dren only. While this is a relatively low vaccination rate, 
it should be noted that a report from the National De-
partment of Health revealed at the time of starting this 
study difference in PVC7 coverage among different Ital-
ian regions, ranging from 20% (Campania, South) to 
95.2% (Emilia-Romagna, North), with a value of 27% in 
Lombardy [25]. 
The estimated annual incidence of IPD in children 
aged less than 5 years was 28.6/100,000, that is similar to 
what has been reported in previuos Italian studies [11-14, 
and also comparable with data from the Active Bacterial 
Core Surveillance, an active population- and laboratory- 
based surveillance system in US, that estimated in 2010 
an incidence of about 25 cases per 100,000 in the popu- 
lation aged 0 - 4 years [26]. In Lombardy, the new strat- 
egy adopted on July 2010 about voluntary mass pneu-
mococcal vaccination offered free of charge in all chil- 
dren, and availability of PCV13, may be expected to im-
pact positively on the coverage pneumococcal vaccination 
and IPD in young children. This active surveillance will 
provide in few years additional valuable data to appraise 
accurately effectiveness of this recent vaccine. 
Regarding the serotype distribution, serotypes 7F and 
19A caused the majority of IPD, as also observed in the 
US [5,24]). This result is comparable with national data 
that estimated 19.2% of pneumococcal meningitis or 
sepsis occurred among children aged less than 5 years 
during in 2009 in Italy being caused by the serotype 19A 
[27. A study conducted in Massachusetts showed through- 
out 2001-2007 period an increase in frequency of sero-
type 19A, that was the most cause of identified IPD cases 
in children (28%) [28]. The relevance of this serotype, 
included in PCV13 but not in PCV7, has been as well 
indicated in South-West Asian countries [e.g., 29], and 
emphasized recently [30,31]. 
Based on the results, the expected overall serotype 
coverage of PCV13 (82.3%) would be within the range 
of values reported in the literature ([10, 23]). Recently, 
Azzari et al. [16] estimated in Italy a national pooled 
serotype coverage of 19.4% and 94% for PCV7 and 
PCV13, respectively. However, it should be noted that in 
the present study, heterogeneity in the serotype distribu-
tion of IPD was found, with a proportion of around 15% 
of serotypes not included in any pneumococcal vaccine, 
as also observed recently in Aguiar et al. [23]. 
Copyright © 2012 SciRes.                                                                                 WJV 
Characteristics of Invasive Pneumococcal Disease in Young Children before the Introduction of  
PCV13 in Lombardy, Italy 
148 
Concerning antimicrobial susceptibility, while the PCV7 
serotypes accounted for the majority of erythromycin re- 
sistant isolates, consistently with recent literature [23], 
the only penicillin resistant serotype was 15C. Moreover, 
it may be interestingly noted that two of the seven chil- 
dren who had received antibiotic therapy during the week 
before hospital admission exhibited serotype 19F and 
23F both resistant against erythromycin. 
Lastly, it may be of interest to point out that, in this 
study, baseline clinical conditions at hospital admission 
did not significantly differ between children with con-
firmed and non confirmed (suspected) IPD, except for 
presence of higher co-morbidity in confirmed IPD cases. 
Moreover, rectal temperature ad hospital admission was 
38˚C or higher in about 85% of children. Although this 
result may be not unexpected it supports about value of 
the US approach to perform blood culture for every feb-
rile young child. 
This study has the major limitation of the small sample 
size of IPD cases, when compared with a recent report 
examining 144 pediatric hospitalized cases with IPD and 
identified serotype from 83 centers in 19 of 20 Italian 
regions [16]. Crudely, it may seem therefore of limited 
novelty, reporting data that may be not unexpected. 
However, it should be noted that in their study, Azzari et 
al. [16] included from Lombardy even fewer cases. An-
other limitation is that real-time-PCR analysis was not 
performed. Indeed, while use of molecular-based meth-
ods for the diagnosis of bacterial infections in blood is 
appealing and useful in research, real-time-PCR with 
blood samples for diagnosis of IPD may lack the sensi-
tivity and specificity necessary for clinical practice [32]. 
Anyway, this study may have some strengths that might 
make it interesting and unique. Firstly, it is the only ac-
tive surveillance of IPD implemented in Lombardy, that 
additionally evaluated the status of IPD up to the intro-
duction of PCV13 in a European geographic region of 
high population density, for which few data exist. These 
data may therefore report useful information to the inter-
national scientific community, health authorities and in-
dustry for improving immunization pneumococcal stra- 
tegies. Secondly, it would give a basis for a subsequent 
meaningful analysis about the impact of PCV13 and po-
tential serotype replacement process. 
5. Conclusion 
As a whole, within the limitations of this study, one can 
conclude that PCV13 mass vaccination in Lombardy 
young children could positively impact on IPD. The dy-
namical role of non-vaccine S. pneumoniae serotypes, 
that might potentially limit the vaccines effectiveness, 
should be monitored through long-term active surveil-
lance, hopefully coordinated across international coun-
tries. 
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